Company Overview
BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Why Investors Should Care
Revenue has grown at a 80.8% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $7.42M (-21.9% YoY); net profit $-2.98M.
- Trailing 12 Months Year-on-year growth — revenue -96.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 80.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 80.83% |
| 1 Year: | -96.60% |
Stock Price Performance
| 1 Year: | -74.87% |
| 6 Months: | -38.60% |
| 3 Months: | -36.07% |
| 1 Month: | -14.63% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)37.58 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 80.8% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 76.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Basic Materials).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BGLC BioNexus Gene Lab Corp. | 1.40 | -1.11 | $4.11M | 0.00% | -36.17% | -33.66% | 80.83% | - |
| 2 | LIN Linde plc NDXSPXR3K | 468.38 | 30.22 | $215.91B | 1.40% | 12.46% | 18.40% | 13.90% | 18.47% |
| 3 | SCCO Southern Copper Corporation R3K | 208.56 | 31.27 | $176.10B | 2.24% | 36.40% | 49.90% | 8.32% | 3.80% |
| 4 | NEM Newmont Corporation SPXR3K | 127.09 | 16.01 | $133.91B | 0.84% | - | 25.91% | 6.53% | 20.15% |
| 5 | RIO Rio Tinto Group | 103.83 | 14.07 | $130.27B | 4.78% | 13.65% | 19.31% | 1.24% | -7.00% |
| 6 | FCX Freeport-McMoRan Inc. SPXR3K | 76.62 | 37.56 | $110.03B | 0.78% | 12.50% | 14.75% | 1.35% | -1.26% |
| 7 | AEM Agnico Eagle Mines Limited | 201.84 | 17.27 | $102.20B | 0.88% | 19.78% | 22.97% | 27.53% | 88.11% |
| 8 | SHW The Sherwin-Williams Company SPXR3K | 326.09 | 30.05 | $79.16B | 1.00% | 21.93% | 65.12% | 6.18% | 8.26% |
| 9 | ECL Ecolab Inc. SPXR3K | 278.11 | 37.33 | $77.96B | 1.05% | 15.10% | 21.96% | 6.55% | 9.74% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 111.30K | 91.62K | 28.09K | 21.64K | 24.17K | 3.07M | 1.10M | 3.09M | 3.45M | 3.09M | 3.58M | 3.03M | 2.49M | 2.58M | 2.38M | 2.57M | 2.55M | 2.38M | 1.97M | 2.63M | 2.14M | 2.26M | 2.54M | 22.84K |
| Gross Profit | -12.53K | 25.65K | 22.37K | 9.27K | 4.62K | 7.67K | 655.31K | 159.29K | 522.22K | 582.57K | 467.61K | 709.19K | 356.33K | 263.97K | 299.50K | 368.90K | 339.71K | 354.33K | 365.03K | 288.72K | 326.54K | 343.49K | 368.02K | 377.69K | -790 |
| Operating Income | - | -39.47K | -55.14K | -60.20K | -69.22K | -50.14K | 1.07M | -33.97K | 237.31K | 342.10K | 139.99K | 372.64K | 34.69K | -137.96K | -65.22K | -50.63K | -272.20K | -2.53M | -79.03K | 259.17K | -1.34M | -618.42K | -611.29K | -702.51K | -540.49K |
| Net Income | 271.86K | -39.47K | -88.96K | -61.47K | -70.40K | -22.03K | 1.07M | -35.84K | 234.46K | 338.74K | 28.26K | 295.32K | 17.07K | -138.66K | -77.40K | -69.07K | -259.25K | -2.61M | -103.76K | 199.10K | -1.35M | -623.33K | -616.17K | -708.99K | -543.58K |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.01 | 0.11 | -0.75 | -0.35 | -0.34 | -0.40 | -0.23 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.47K | 8.20K | 10.44K | 12.14K | 12.56K | 14.88K | 14.49K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 212.33K | 126.95K | 11.39M | - | 10.93M | 9.77M | 9.51M | 7.42M |
| Cost of Revenue | - | - | - | - | 9.67M | 8.44M | 8.22M | 6.34M |
| Gross Profit | 28.77K | 55.89K | 1.72M | - | 1.26M | 1.33M | 1.29M | 1.09M |
| Operating Expenses | - | - | - | - | 1.55M | 4.41M | 3.25M | 4.24M |
| Operating Income | 59.90K | -275.70K | 1.27M | - | -291.18K | -3.08M | -1.96M | -3.16M |
| EBITDA | - | - | - | - | -185.76K | -2.49M | -1.42M | -2.80M |
| Interest Expense | - | - | - | - | 12.48K | 13.93K | 21.15K | 19.54K |
| Pretax Income | - | - | - | - | -303.66K | -2.61M | -1.59M | -2.98M |
| Tax Provision | - | - | - | - | 52.31K | 21.53K | 3.49K | 0 |
| Net Income | 26.45K | -246.47K | 1.09M | - | -355.97K | -2.63M | -1.60M | -2.98M |
| Diluted EPS | - | - | - | - | -0.46 | -1.66 | -0.90 | -1.61 |
| R&D Expense | - | - | - | - | - | 54.98K | 47.51K | 50.67K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2018 | Dec 2018 | Dec 2019 | Jan 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.65M | 1.23M | - | 10.12M | 9.57M | 8.74M | 11.40M | 10.43M | 9.25M |
| Total Equity | 94.63K | 1.52M | 1.12M | 1.12M | 6.66M | 7.18M | 6.67M | 9.66M | 8.32M | 8.61M |
| Cash & Equivalents | - | 1.26M | 859.08K | - | 2.79M | 2.12M | - | - | 2.89M | 2.49M |
| Total Liabilities | - | 130.31K | 108.87K | - | 3.45M | 2.39M | 2.08M | 1.74M | 2.11M | 637.86K |
| Current Liabilities | - | 62.89K | 51.57K | - | 3.37M | 2.33M | 2.00M | 1.63M | 1.95M | 520.96K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -274.08K | -217.27K | 552.68K | 9.16K | 551.82K | -1.82M | -2.09M | -1.84M |
| Investing Cash Flow | -51.70K | -12.82K | 1.32M | -490.57K | -450.50K | -1.79M | 418.20K | 944.75K |
| Financing Cash Flow | 742.94K | -180.81K | -4.95K | -28.22K | 108.17K | 6.27M | 3.98K | 298.84K |
| Capital Expenditure | 39.62K | -12.82K | -421.62K | -3.16K | -0 | -149.40K | -226.99K | -36.97K |
| Free Cash Flow | -234.46K | -230.09K | 131.06K | 6.00K | 551.82K | -1.97M | -2.32M | -1.88M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 13.5% | 44.0% | 15.1% | - | 11.5% | 13.6% | 13.6% | 14.6% |
| Operating Margin % | 28.2% | -217.2% | 11.2% | - | -2.7% | -31.5% | -20.6% | -42.5% |
| Net Margin % | 12.5% | -194.1% | 9.6% | - | -3.3% | -26.9% | -16.8% | -40.2% |
| ROE % | 1.7% | -22.0% | 16.4% | - | -5.3% | -27.2% | -19.2% | -34.6% |
| ROCE % | 3.8% | -23.4% | 18.9% | - | -4.3% | -31.5% | -23.1% | -36.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | HRT Financial LP | 0.49% | 14.28K | $22.42K |
| 2 | Caitong International Asset Management Co., Ltd | - | 1 | $1 |
| 3 | UBS Group AG | - | 101 | $158 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BGLC
BioNexus Gene Lab Corp (BGLC) grants CEO 338,709 fully vested shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxONzlGUWJYUlE4NkU3RVVKM2dOVFdwdENRbkNOVFc0UTBjN1BCSXl6SDZXbmdxUzM1S25KVFllemNLM05YUC1zSlFKbHNEOFJ3SklVQjVaNDB3WWZrc2JsM2RUN3JMcTJfa05ld0M3UkZBZmhnMTF5Z3FQOGUxQVJZcDZSakJIaExuWmRGRU…
BGLC - BioNexus Gene Lab Corp Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5XMGdjVnA0aDViX0JtNE1HNjdTU1pSem1FTlAybDNZeTYyT0E1dEM3cHJUN0FnZnZ3N2Y3QUJIakNfYjFEQWc?oc=5" target="_blank">BGLC - BioNexus Gene Lab Corp Stock Price and Quote</a> <font…
BGLC | BioNexus Gene Lab Corp Insider Trading - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE1hN0FuVmR1X3dtUXFIMDd0WkJhaTMwS3l2T1B3dHBCVHVXdTA0eW5CdW1lbkxYaTk5ZDNqQ3dqZVBvQkdNLWx2a0xxLWFSQ1lhVWMyTi1rZi00blFa?oc=5" target="_blank">BGLC | BioNexus Gene Lab Corp Insider Tradi…
BGLC Stock Tumbled Over 13% Today: Why Is VitaGuard Commercialization Agreement Drawing Investor Attention? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxNVWM4c1p1N1NRbXR6bTlhZUhGZmVIZVJsaHBadlpreXYxNWl1VndVenJNaDRzR3BaUGFnck5wbUhpVjJzOFU5WHJxTUp0RklQcmRWemhIMGhFQVotUWdDM1BsNzdld0xSbS00dURxVlBMNkRUWWlRNmF0WF9JUmdTSE9pTW1HalJpY0lhNj…
BioNexus Gene Lab Corp (BGLC) CFO receives 96,774-share equity award - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNNUlUd0Y0SFZDakJjUlFja01sd2wtTFJKLUxPMEwxOWI3WnBkeTM1QS14elpFU082Q1l2aGI4ZVB4S0xWYi0yUGtoZmtYNkFTeGNTQnQxdzdYOWRGNVE5Q1RBaGw5VnlWcjkwYl8yakFmSmdod0dXUldleGp3MVROMWRtMnNEOWdWV2xhdV…
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization - BioSpace
<a href="https://news.google.com/rss/articles/CBMiggJBVV95cUxPenlzbVNpei1nLU9xZldhdk5YZ3ZTZDlVWWNUYkNCYUY1Q184MlRQZ0RoalQwWVVXWVNoWVNoOHlFOXhRWmg4SjFYUkVMUUhoMmFFZmd5aURQd0ZLUW1NSWJObmJxZ1htWGdmY2VGZFZvN2xpZGJLY1AwbFc5clJya1UwX1lLNVdKcVMwd3…
BGLC — Frequently Asked Questions
What is the current share price of BioNexus Gene Lab Corp. (BGLC)?
As of 2026-09-19 21:16 PDT, BioNexus Gene Lab Corp. (BGLC) trades at $1.40 on NasdaqCM. Its 52-week range is $1.32 to $6.00.
What is the market capitalisation of BGLC?
BioNexus Gene Lab Corp. (BGLC) has a market capitalisation of $4.11M on NasdaqCM.
What is the P/E ratio of BGLC?
BGLC trades at a trailing price-to-earnings (P/E) ratio of -1.11. The industry average P/E is 22.16. Its price-to-book (P/B) ratio is 0.45.
What is the return on equity (ROE) of BGLC?
BGLC has a return on equity (ROE) of -33.66%. Its return on capital employed (ROCE) is -36.17%.
Is BGLC a good stock to buy?
This page provides a data-driven analysis of BioNexus Gene Lab Corp. (BGLC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.